vendredi 22 avril 2016

MAPREG

Mapreg, the Paris-based clinical stage pharmaceutical company created in 2000, is developing an innovative new drug that targets neuronal microtubules, providing a new way of treating depression. The company, founded by Professor Etienne Baulieu, has received significant support and contributions from Charles Rosier and other investors like Generali, allowing, the streamlined and expert organisation to conduct research and development with the objective of finding cures and treatments for neurological conditions such as depression, neurodegeneration and trauma. The conditions are often caused by alterations to microtubules, which consequently endanger neurons, both structurally and functionally. Mapreg develop proprietary drugs that specifically protect or repair these neuronal microtubules through a target known as MAP-2 (Microtubule Associated Protein-2). MAP-2 is an essential component to the integrity of microtubules. It is also a receptor for Pregnenolone, a neurologically active neurosteroid that has unwanted side-effects. MAPREG pharmaceuticals involve pregnenolone-type compounds that act on the nervous system without causing harm.
Charles Rosier


In 2016, Mapreg are aiming to undertake clinical trials of its lead drug, MAP4343, to establish a brand new way of treating the life-debilitating, and potentially life-threatening, illness that is depression. The company will test MAP4343 on patients who have not responded to the anti-depressants that are currently on the market. Mapreg believe that a cutting-edge approach is needed as many currently available drugs could take up to a month to work, have immediate negative side effects and do not always work (30-40% of patients experience Treatment Resistant Depression). These drugs also all work in the same way, by modulating levels of the neurotransmitters, Serotonine and Norepinephrine. Therefore, with MAP4343, Mapreg are working to provide an entirely new way of treating depression by protecting microtubules, ensuring effective, rapid and safe treatment for everyone. The drug also uses the aforementioned neurosteroid, Pregnenolone, which has been proven to have a positive effect on human depression, making the success of MAP4343 highly likely.

So, what makes this an attractive and opportune investment? There will be two parallel trials undertaken for alcohol addiction and depression, meaning that the conception of MAP4343 could be twofold. Both trials will benefit from funding from French and American health agencies. Furthermore, MAPREG intend to make the drug available in two forms: a pill and an injectable, meaning that any neurodisorder, whether acute or chronic, can be addressed. This particular round of investment will catapult MAPREG beyond human proof of concept, allowing it to target several neurological markets. Completion is expected in three years, following human proof of concept, and the drug holds extremely high value in relation to potential target markets.

mercredi 24 juillet 2013

Charles Rosier Biography

charles rosier

In nineteen ninety three, Charles Rosier registered ESCP Europe, the earliest business school globally, where he received a specific training regarding EU and international organization. He finished school in '96.

At the investment group BTG Pactual since 2010, Charles Rosier is liable for establishing strategies as well as optimizing BTG Pactual's interactions with its partners and its consumers outside Brazil, specially in Europe, South America, the Middle East and Asia.



Charles Rosier has been among the initial investors in MPOWERD (Micro Power Design), a business providing economical photo voltaic lighting meant for the impoverished lands along with responsible buyers within rich nations.

A pop music and cinema aficionado, Charles Rosier has taken part in the release of « Golden Door », (awarded at the 2006 Venice Film Festival) and in addition allowed artist Lola to launch a music work.

Apart from his career as well as his philanthropic passions, Charles Rosier practices various sports such as tennis, snow-boarding, wind-surfing or kite surfing. Charles Rosier talks French, the English language, the Spanish language and is at present learning Portuguese.

More about me : my website